Admescope acquires MetaSafe to build European ADME-focused CRO

Handshake business deal executives
The merger aims to provide both preclinical and clinical ADME and toxicology services to support lead candidate optimization. (Pixabay)

Admescope has acquired Swedish contract research organization MetaSafe AB, which focuses on metabolic research and drug biotransformation. Financial terms were not disclosed.

Oulu, Finland-based Admescope, which offers services in toxicology and pharmacokinetics, said it hopes the purchase will strengthen its drug metabolism services in clinical-phase projects, and that it will also provide access to MetaSafe’s laboratory facility.

“We are excited about the acquisition, and warmly welcoming MetaSafe’s experienced experts as a part of the Admescope team,” Admescope CEO Ari Tolonen said in a statement. “Due to the excellent synergy between the companies' service portfolios and operative models, this acquisition will add value for both MetaSafe’s and Admescope’s customers, as together we create a more comprehensive service offering with strengths from the both companies.”

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

The merger aims to create a unique ADME-focused CRO, providing both preclinical and clinical services to support lead candidate optimization.

“MetaSafe’s and Admescope’s services are highly complementary, and in the future we will be in a position to provide our customers with a comprehensive offering from a single source for everything relating to ADME services in order to ensure early and late lead candidate optimization,” said Johanna Haglund, CEO of MetaSafe.